Alexion, AstraZeneca's rare-disease group, maintains a major UK presence developing complement-based therapies for ultra-rare disorders.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.